In addition, we showed that the DNA methylation levels of NFE2L3 were significantly lower in tumor tissues than in normal tissues in most of the NFE2L3 methylation CpG sites in TCGA pan-cancer (PANCAN) cohort, including cg16882373, cg18844118, cg13118545, cg14534464, cg03886242, cg04995722, cg07986525, cg14684457, cg21699330, cg10536999, cg08822075, cg12510708, cg19310148, cg07945582, and cg13855897 (Figure 5B). This evidence concerns the gene NFE2L3 and neoplasm.